CLPTHIGH SIGNALFINANCIAL10-K

CLPT shows massive 405% increase in total liabilities alongside significant acquisition activity, evidenced by trademark additions and dramatically worsened operating cash flow.

The company appears to have completed a major acquisition (adding IRRAS and IRRAFLOW trademarks) that fundamentally changed its capital structure, with debt increasing nearly 400% to $49.1M. While cash more than doubled, the 167% deterioration in operating cash flow to -$23.9M raises concerns about the combined entity's profitability and cash burn rate.

Comparing 2026-03-17 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

CLPT's financial profile was dramatically transformed, with total liabilities surging 405% to $69.7M and debt quadrupling to $49.1M, indicating a major acquisition or financing event. While total assets nearly doubled to $97.7M and cash increased 128% to $45.9M, operating cash flow deteriorated significantly to -$23.9M from -$8.9M, suggesting the expanded operations are burning cash at an accelerated rate. The 92% reduction in interest expense despite higher debt levels and 38% increase in SG&A expenses further confirm a major business combination that has yet to demonstrate operational synergies.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
+405.3%
$13.8M→$69.7M

Liabilities grew 405.3% — significant increase in debt or obligations, assess impact on financial flexibility.

Total Debt
Balance Sheet
+393.3%
$9.9M→$49.1M

Debt increased 393.3% — substantial leverage increase; assess whether deployed for growth or covering losses.

Operating Cash Flow
Cash Flow
-167.3%
-$8.9M→-$23.9M

Operating cash flow fell 167.3% — earnings quality concerns; investigate working capital changes and non-cash items.

Total Assets
Balance Sheet
+149.4%
$39.2M→$97.7M

Asset base grew 149.4% — expansion through organic growth, acquisitions, or capital deployment.

Cash & Equivalents
Balance Sheet
+128.4%
$20.1M→$45.9M

Cash position surged 128.4% — strong cash generation or capital raise providing significant financial cushion.

Interest Expense
P&L
-91.7%
$973K→$81K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Current Assets
Balance Sheet
+90.6%
$33.4M→$63.6M

Current assets grew 90.6% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
+89.8%
$275K→$522K

Capital expenditure jumped 89.8% — major investment cycle underway; assess returns on deployment.

Accounts Receivable
Balance Sheet
+39%
$4.7M→$6.5M

Receivables surged 39% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

SG&A Expense
P&L
+37.5%
$12.0M→$16.5M

SG&A up 37.5% — significant increase in sales or administrative costs, monitor impact on operating leverage.

LANGUAGE CHANGES
NEW — 2026-03-17
PRIOR — 2025-02-26
ADDED
60 Trademarks, Trade Names and Service Marks ClearPoint Neuro , ClearPoint , SmartFlow , SmartFrame , SmartGrid , Inflexion , ClearPoint Maestro , SmartFrame Array , SmartFrame OR , ClearPoint Neuro Orchestra , ClearPoint Prism , ClearPointer , When Your Path is Unclear, We Point The Way , ClearPoint Advanced Laboratories , IRRAS , and IRRAFLOW are all trademarks of ClearPoint Neuro, Inc.
All statements, other than statements of historical fact, in this Annual Report, including statements relating to our expectations for performance, revenues and costs, and the adequacy of cash and cash equivalent balances and short-term investments to support operations and meet future obligations, are forward-looking statements.
We caution you that the forward-looking statements in this report are based on a combination of facts, factors currently known by us and our projections of the future, about which we cannot be certain.
In addition, statements that we believe and similar statements reflect our beliefs and opinions on the relevant subject.
These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.
+7 more — sign up free →
REMOVED
52 Trademarks, Trade Names and Service Marks ClearPoint Neuro , ClearPoint , SmartFlow , SmartFrame , SmartGrid , Inflexion , SmartTwist , SmartTip , ClearPoint Maestro , SmartFrame Array , SmartFrame OR , ClearPoint Neuro Orchestra , ClearPoint Prism , SmartFlow Flex , ClearPointer , When Your Path is Unclear, We Point The Way , and ClearPoint Advanced Laboratories are all trademarks of ClearPoint Neuro, Inc.
The forward-looking statements relate to our expectations for performance, revenues and costs, and the adequacy of cash and cash equivalent balances and short-term investments to support operations and meet future obligations.
Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain.
Our ClearPoint system may not achieve broad market adoption and our future business growth is dependent upon marketing and selling our ClearPoint system, and other new products, in the operating room.
Our internal manufacturing operations are generally conducted at a single location, which may limit our ability to provide an adequate supply of our products, and any disruption at our manufacturing facility could render us unable to produce our products, increase our expenses and decrease our revenue.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →